Review
| Rev Diabet Stud,
2010,
7(2):144-157 |
DOI 10.1900/RDS.2010.7.144 |
Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Insulin-Dependent Diabetes
Carmen Fotino1, Camillo Ricordi1,2,3,4, Vincenzo Lauriola1, Rodolfo Alejandro1,3, Antonello Pileggi1,2
1Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL, USA
2DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA
3Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA
4Department of Biomedical Engineering, Miller School of Medicine, University of Miami, Miami, FL, USA
Address correspondence to: Antonello Pileggi, e-mail: apileggi@med.miami.edu
Keywords: bone marrow-derived stem cell, diabetes, mesenchymal stem cell, transplant, islet transplantation, beta-cell replacement, chimerism, clinical trial, tolerance
Abstract
The bone marrow is an invaluable source of adult pluripotent stem cells, as it gives rise to hematopoietic stem cells, endothelial progenitor cells, and mesenchymal cells, amongst others. The use of bone marrow-derived stem cell (BMC) transplantation (BMT) may be of assistance in achieving tissue repair and regeneration, as well as in modulating immune responses in the context of autoimmunity and transplantation. Ongoing clinical trials are evaluating the effects of BMC to preserve functional beta-cell mass in subjects with type 1 and type 2 diabetes, and to favor engraftment and survival of transplanted islets. Additional trials are evaluating the impact of BMT (i.e., mesenchymal stem cells) on the progression of diabetes complications. This article reviews the progress in the field of BMC for the treatment of subjects with insulin-dependent diabetes, and summarizes clinical data of pilot studies performed over the last two decades at our research center by combining allogeneic islet transplantation with donor-specific BMC.
Fulltext:
 HTML ,  PDF
(712KB)
This article has been cited by other articles:
|
Moving from the laboratory bench to patients’ bedside: considerations for effective therapy with stem cells
Sherman LS, Munoz J, Patel SA, Dave MA, Paige I, Rameshwar P
Clin Transl Sci 2011. 4(5):380-386
|
|
|
Human placenta-derived mesenchymal stem cells and islet-like cell clusters generated from these cells as a novel source for stem cell therapy in diabetes
Kadam S, Muthyala S, Nair P, Bhonde R
Rev Diabet Stud 2010. 7(2):168-182
|
|
|
The quest for tissue stem cells in the pancreas and other organs, and their application in beta-cell replacement
Houbracken I, Bouwens L
Rev Diabet Stud 2010. 7(2):112-123
|
|
|
